MYCN and cancer: Amplification of these genes has been widely reported to improve cancer proliferation, survival, and invasiveness.14,17–19 Notably, inhibitors targeting the EGFR pathway (erlotinib and gefitinib) and the PI3K/AKT/mTOR pathway (Alpelisib) have been developed as anti-cancer therapeutics.20,21 At last, gains in the 2p region where the proto-oncogene MYCN is located occurred later.